Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 2Gastrointestinal 2Endocrine 2Dermatologic 2Thoracic 1Sarcoma 1Other solid neoplasm 1Gynecologic 1Genitourinary 1CNS 1

Conditions

Mesothelioma, Malignant 120Mesothelioma 70Solid Tumor 46Solid Tumors 33Retinoblastoma 27Solitary Fibrous Tumor, Pleural 20Sarcoma 17Advanced Solid Tumor 16Advanced Solid Tumors 15Lung Neoplasms 13Small Cell Lung Carcinoma 12Carcinoma, Non-Small-Cell Lung 11Osteosarcoma 9Neuroblastoma 8Ovarian Neoplasms 7Unspecified Adult Solid Tumor, Protocol Specific 6Solid Tumor, Adult 6Colorectal Neoplasms 6Cholangiocarcinoma 6Central Nervous System Neoplasms 6Carcinoma, Renal Cell 6Uterine Cervical Neoplasms 5Thyroid Neoplasms 5Stomach Neoplasms 5Neoplasms 5Melanoma 5Medulloblastoma 5Chondrosarcoma 5Carcinoma, Hepatocellular 5Breast Neoplasms 5

Interventions

atezolizumab 1Immunoglobulin G 1Disulfides 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Adenocarcinoma, Mucinous × Other solid neoplasm × Clear all
NCT03074513 2026-03-11

Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
133 enrolled
DermatologicEndocrineHead & NeckOther solid neoplasmThoracic

Nasopharyngeal Carcinoma, Mesothelioma, Malignant, Adenocarcinoma, Mucinous, Adenoma, Islet Cell, Nasopharyngeal Neoplasms, Carcinoma, Merkel Cell, Carcinoma, Neuroendocrine

Data powered by HemOnc (CC BY 4.0) Colophon âš¡